Pair page
HGH Fragment 176-191 with Tesofensine
Mechanism-tag overlap and published literature for HGH Fragment 176-191 and Tesofensine, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
growth-hormone-c-terminal-fragment
triple-monoamine-reuptake-inhibitor
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying HGH Fragment 176-191 and Tesofensine have published these mechanism-level observations. Not a co-administration recommendation.
Combining a central-acting appetite modulator (tesofensine; tirzepatide; semaglutide) with a peripheral lipolytic agent (HGH Fragment) is the "central appetite + peripheral lipid mobilization" body-composition framework. Requires clinician oversight; compounds safety considerations.
Quick facts
HGH Fragment 176-191
Tesofensine
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2013 | HGH Fragment 176-191 | Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. (AOD-9604 human tolerability data.) | human study |
| 2001 | HGH Fragment 176-191 | Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 117132… PMID 11713212 | preclinical, in vivo |
| 2000 | HGH Fragment 176-191 | Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146361. (AOD-9604 preclinical metabolic characterization.) PMID 11146361 | preclinical, in vivo |
| 2000 | HGH Fragment 176-191 | Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 10913053. (Oral bioavailability and lipid-metabolism effects of the GH frag… PMID 10913053 | pharmacology |
| — | HGH Fragment 176-191 | U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Category 2 list. FDA.gov. | regulatory / registry |
| 1999 | HGH Fragment 176-191 | Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet. 1999;353(9156):895. PMID: 10093986. (Context for GH-family detection.) PMID 10093986 | research article |
| 1988 | HGH Fragment 176-191 | Salem MA. A possible direct lipolytic effect of growth hormone. Proc Soc Exp Biol Med. 1988;187(1):1-6. PMID: 3340595. (Mechanistic context for GH lipolytic activity.) PMID 3340595 | research article |
| 1981 | HGH Fragment 176-191 | Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med. 1981;305(3):123-131. PMID: 7242610. (Reference for full-length GH effects, highlighting the differe… PMID 7242610 | research article |
| 1978 | HGH Fragment 176-191 | Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526. PMID: 645887. (Early structural dissection of GH C-terminal activity.) PMID 645887 | research article |
| 2026 | Tesofensine | Saniona AB. Tesomet — Pipeline. saniona.com/pipeline/tesomet. Accessed April 2026. (Phase 2b PWS and hypothalamic obesity trials voluntarily paused due to funding limitations; not safety/efficacy.) | human trial, Phase 2 |
| 2008 | Tesofensine | Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Nov 29;372(9653):1906-1913. doi: 10.1016/S0140-… PMID 18950853 | human trial, Phase 2 |
| — | Tesofensine | ClinicalTrials.gov. NCT03845075 — Randomized Controlled Trial of Tesomet in Adults With Hypothalamic Obesity. NCT03149445 — Phase 2a Tesomet in Prader-Willi Syndrome. NCT00394667 — Effect of Tesofensine on Weight Reduction in Patients With Obesity. clinicaltrials.gov. | human trial, Phase 2 |
| 2022 | Tesofensine | Huynh KD, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022 Apr 28;186(6):687-700. doi: 10.1530… PMID 35294397 | human trial |
| 2009 | Tesofensine | Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 28;373(9665):719. doi: 10.1016/S0140-6736(09)60433-5. PMID: 19249626. PMID 19249626 | human trial |
| 2007 | Tesofensine | Hauser RA, Salin L, Juhel N, Konyago VL, et al. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007 Feb 15;22(3):359-365. doi: 10.1002/mds.21258. | human trial |
| 2009 | Tesofensine | Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16. PMID: 19777399. PMID 19777399 | human study |
| 2008 | Tesofensine | Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008 Jun;16(6):1363-9. PMID: 18356831. PMID 18356831 | human study |
| 2008 | Tesofensine | Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol. 2008 May;65(5):577-83.… PMID 18474731 | human study |
| 2013 | Tesofensine | Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122.… | preclinical, in vivo |
| 2010 | Tesofensine | Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of α1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010 May;35(7):1464-76. d… | preclinical, in vivo |
| 2010 | Tesofensine | Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur… | preclinical, in vivo |
Related pair pages
More research context
Frequently asked
Have HGH Fragment 176-191 and Tesofensine been studied together?
Researchers have published mechanistic-level co-administration discussion of HGH Fragment 176-191 and Tesofensine. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do HGH Fragment 176-191 and Tesofensine share?
HGH Fragment 176-191 and Tesofensine do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of HGH Fragment 176-191 and Tesofensine?
HGH Fragment 176-191: Not approved; Category 2. Tesofensine: Investigational. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on HGH Fragment 176-191 and Tesofensine?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the HGH Fragment 176-191 profile and the Tesofensine profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026